Current state of knowledge of hepatic encephalopathy (Part V): clinical efficacy of L-ornithine-L-aspartate in the management of HE

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Metabolic brain disease

• Publication date

  2016-11-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11011-016-9912-0PMID 27838865
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral l‐ornithine‐l‐aspartate in minimal hepatic encephalopathy: A randomized, double‐blind, placebo‐controlled trial

  2014influential reference
• l‐ornithine‐l‐aspartate for hepatic encephalopathy in patients with cirrhosis: A meta‐analysis of randomized controlled trials

  2013influential reference
• Modulation of neural activation following treatment of hepatic encephalopathy

  2013cited by this paper
• Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure.

  2011cited by this paper
• [Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy].

  2010cited by this paper
• Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study.

  2009influential reference
• Clinical Efficacy of L-Ornithine–L-Aspartate in the Management of Hepatic Encephalopathy

  2002cited by this paper
• Treatment with L-ornithine-L-aspartate infusion restores muscle protein synthesis responsiveness to feeding in patients with cirrhosis

  1999cited by this paper
• L‐Ornithine‐L‐aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure

  1999cited by this paper
• Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.

  1998cited by this paper
• Therapeutic efficacy of L‐ornithine‐L‐aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo‐controlled, double‐blind study

  1997cited by this paper
• Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design.

  1993influential reference
• Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy.

  1990cited by this paper
• [Therapy of severe hyperammonemia].

  1972cited by this paper

• Analysis and mining of L-ornithine L-aspartate adverse events based on FAERS database

  2025cites this paper
• Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials.

  2024cites this paper
• Hyperammonemia in Inherited Metabolic Diseases

  2021cites this paper
• Posteriores reversibles enzephalopathisches Syndrom und Hyperammonämie: zwei Entitäten für Hirnödem und Status epilepticus bei einer Patientin nach Lungentransplantation

  2020cites this paper
• [Posterior reversible encephalopathy syndrome and hyperammonemia: two entities causing cerebral edema and status epilepticus in a female patient after lung transplantation].

  2020cites this paper
• Fatal neurological complication after liver transplantation in acute hepatic failure patient with hepatic encephalopathy

  2018cites this paper
• Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

  2018cites this paper
• L‐ornithine L‐aspartate in bouts of overt hepatic encephalopathy

  2018cites this paper
• [Prevention and treatment of hepatic encephalopathy].

  2017cites this paper
• Vitamins, Amino Acids and Drugs and Formulations Used in Nutrition

  2017cites this paper